ResMed Inc (RMD) stock
RMDNYSESurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RSMDF
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 21/3012% below fair value
$239.53+0.64 (+0.27%)
Close on Nov 13, 2026Market cap $33.69BP/E 21.8Yield 1.00%
ResMed EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
ResMed's EPS for the twelve months ending Sep 30, 2026 was $10.98, up 12.4% year over year. For fiscal 2026 it was $10.43, up 9.7% from the year before. Over ten years it grew 15.4% a year on average. The highest annual figure on record is $10.43 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $10.43 | +9.7% |
| FY2025 | Jun 30, 2025 | $9.51 | +37.4% |
| FY2024 | Jun 30, 2024 | $6.92 | +13.6% |
| FY2023 | Jun 30, 2023 | $6.09 | +14.9% |
| FY2022 | Jun 30, 2022 | $5.30 | +63.6% |
| FY2021 | Jun 30, 2021 | $3.24 | -24.1% |
| FY2020 | Jun 30, 2020 | $4.27 | +52.5% |
| FY2019 | Jun 30, 2019 | $2.80 | +27.9% |
| FY2018 | Jun 30, 2018 | $2.19 | -8.8% |
| FY2017 | Jun 30, 2017 | $2.40 | -3.6% |
| FY2016 | Jun 30, 2016 | $2.49 | +0.8% |
| FY2015 | Jun 30, 2015 | $2.47 | +3.3% |
| FY2014 | Jun 30, 2014 | $2.39 | +13.8% |
| FY2013 | Jun 30, 2013 | $2.10 | +22.8% |
| FY2012 | Jun 30, 2012 | $1.71 | +18.8% |
| FY2011 | Jun 30, 2011 | $1.44 | +17.1% |
| FY2010 | Jun 30, 2010 | $1.23 | +29.5% |
| FY2009 | Jun 30, 2009 | $0.95 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $2.92 | +23.2% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $2.64 | +2.3% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $2.74 | +10.5% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $2.68 | +14.5% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $2.37 | +12.3% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $2.58 | +30.3% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $2.48 | +21.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $2.34 | +64.8% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $2.11 | +41.6% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $1.98 | +26.9% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $2.04 | +29.1% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $1.42 | -7.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $1.49 | +4.2% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $1.56 | +17.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $1.58 | +29.5% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $1.53 | +11.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $1.43 | +2.9% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $1.33 | 0.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $1.22 | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $1.37 | +11.4% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $1.39 | +13.9% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.33 | +9.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$0.54 | -148.2% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $1.23 | +11.8% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.22 | +47.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $1.22 | +159.6% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $1.12 | +53.4% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $1.10 | +27.9% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $0.83 | +13.7% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $0.47 | -38.2% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $0.73 | -3.9% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $0.86 | +1128.6% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $0.73 | +21.7% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $0.76 | +7.0% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $0.76 | +22.6% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $0.07 | -87.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $0.60 | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $0.71 | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $0.62 | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $0.54 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?